At IFM Therapeutics, they work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body’s first line of immunological response, and an essential component of immune function.

Biotechnology

IFM Therapeutics

H. Martin Seidel

Sujen Lai, PMP

Shankar Venkatraman

Eicke Latz

Ayman F. El-Kattan

Chris Lindblom, CPA and MBA

Ann Santilli

Christopher M. Lindblom

Ed Olhava

Dennis Dean

The board of directors at IFM Therapeutics has a long and varied history. Members have experience with Dioscure Therapeutics, The University of Bonn, Boston Children's Hospital, Whitehead Institute, Rheinische Friedrich-Wilhelms-Universität Bonn, University of Bonn Medical Center, Abingworth, Alnylam Pharmaceuticals, Millennium Pharmaceuticals, and Dana Farber Cancer Institute. They also boast a variety of educational backgrounds including Biochemistry from Technical University of Munich, Cell Biology and Virology from ETH Zürich, and Humanmedizin from Eberhard Karls Universität Tübingen.

Board of Directors

Leadership Team

Founding Team

Board of Directors

About

Team members

Other teams at IFM Therapeutics

Leadership Team

Founding Team